1300017J02Rik Inhibitors
Chemical inhibitors of protein 1300017J02Rik play a significant role in modulating its activity by targeting various kinases and enzymes that are integral to its function. Staurosporine and Go6983 are broad-spectrum kinase inhibitors that can suppress the phosphorylation activity necessary for the activation of protein 1300017J02Rik, while specifically targeting protein kinase C (PKC), as does Bisindolylmaleimide I, leading to a decrease in the phosphorylation state of the protein. This reduction in phosphorylation directly affects the protein's activity, as phosphorylation is a common post-translational modification that regulates protein function. Wortmannin and LY294002 specifically inhibit phosphoinositide 3-kinases (PI3K), enzymes that are pivotal in cell signaling pathways. By inhibiting PI3K, these chemicals disrupt the activation of downstream targets, which are critical for the functional activity of protein 1300017J02Rik.
In addition, PD98059 and U0126 target the MAPK/ERK pathway by inhibiting mitogen-activated protein kinase kinase (MEK), which can lead to a decrease in the ERK pathway signaling that may be necessary for the phosphorylation and subsequent activation of protein 1300017J02Rik. Similarly, SB203580 and SP600125 target different components of the MAPK pathway; SB203580 inhibits p38 MAP kinase, and SP600125 inhibits c-Jun N-terminal kinase (JNK), which can result in reduced signaling for stress and inflammatory responses that protein 1300017J02Rik may be involved in. Rapamycin, by inhibiting mammalian target of rapamycin (mTOR), a central regulator of cell growth, can indirectly affect the activity of protein 1300017J02Rik by modulating growth-related signals. Lastly, PP2 and Y-27632 target tyrosine kinases and Rho-associated protein kinases, respectively, with PP2 inhibiting Src family kinases, thus preventing tyrosine phosphorylation, and Y-27632 inhibiting ROCK, which affects actin cytoskeleton dynamics and potentially influences the signaling pathways involving protein 1300017J02Rik.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine inhibits a variety of protein kinases, which could lead to the inhibition of kinase-dependent phosphorylation of 1300017J02Rik, thus preventing its activation and subsequent function. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a specific inhibitor of phosphoinositide 3-kinases (PI3K), which are involved in various signaling pathways. Inhibition of PI3K can lead to decreased activation of downstream targets that may be required for the full functional activity of 1300017J02Rik. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002, like Wortmannin, inhibits PI3K. By targeting this kinase, LY294002 can reduce signaling through pathways that are necessary for the proper functioning of 1300017J02Rik. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits mammalian target of rapamycin (mTOR), a central regulator of cell growth and proliferation. Inhibition of mTOR can indirectly inhibit the activity of 1300017J02Rik by affecting the pathways that control growth-related signals and processes where 1300017J02Rik might play a role. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is an inhibitor of mitogen-activated protein kinase kinase (MEK), which is part of the MAPK/ERK pathway. By inhibiting MEK, PD98059 can inhibit the ERK pathway, which might be necessary for the phosphorylation and activation of 1300017J02Rik. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 also inhibits MEK1/2 in the MAPK/ERK pathway. By doing so, the chemical can prevent the activation of downstream proteins that may be involved in the functional activation of 1300017J02Rik. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a specific inhibitor of p38 MAP kinase, part of the MAPK pathway. Inhibition of p38 MAP kinase can lead to reduced stress response signaling, potentially diminishing the functional activity of 1300017J02Rik if it is involved in cellular response to stress. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 inhibits c-Jun N-terminal kinase (JNK), which is implicated in stress and inflammatory response signaling. This inhibition can reduce the functional activity of 1300017J02Rik if it is involved in pathways related to these responses. | ||||||
Gö 6983 | 133053-19-7 | sc-203432 sc-203432A sc-203432B | 1 mg 5 mg 10 mg | $105.00 $299.00 $474.00 | 15 | |
Go6983 is a potent protein kinase C (PKC) inhibitor. By inhibiting PKC, Go6983 can reduce the phosphorylation state of 1300017J02Rik, leading to decreased activity if 1300017J02Rik is regulated by PKC-mediated phosphorylation. | ||||||
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $105.00 $242.00 | 36 | |
Bisindolylmaleimide I also targets PKC, potentially reducing the phosphorylation and activity of 1300017J02Rik if PKC is involved in its activation. | ||||||